Basal cell carcinoma (BCC), the most common form of human cancer, is understood to be associated with activation of the sonic hedgehog pathway, through lossof-function mutations of tumor suppressor PTCH1 or gain-of-function mutations of smoothened. Interferon (IFN)-based therapy is quite effective in BCC treatment, but the molecular basis is not well understood. Here we report a novel mechanism by which IFNa mediates apoptosis in BCCs. In the presence of IFNa, we observed increased apoptosis in a BCC cell line ASZ001, in which PTC is null, and therefore with constitutive activation of the sonic hedgehog pathway. We demonstrate that SMO agonist Ag-1.4 mediates activation of extracellular signalregulated kinase (Erk) phosphorylation, which is abrogated by IFNa in sonic hedgehog responsive C3H10T1/2 cells. In transient transfection experiments, we demonstrate that IFNa inhibits Erk phosphorylation and serum response element activation induced by expression of SMO, Gli1, PDGFRa and activated Raf, but not activated mitogen-activated Erk-regulating kinase (Mek), suggesting that IFNa targets mainly on Mek function. We further show that IFNa induces expression of Fas in BCC cells through interfering with Mek function. The role of the Fas-L/Fas signaling axis in IFNa-mediated apoptosis is demonstrated by the fact that addition of Fas-L neutralizing antibodies, just as caspase-8 inhibitor Z-IETD-FMK, effectively prevents IFNa-mediated apoptosis. Thus, our data indicate that IFNa-based BCC therapy induces Fas expression and apoptosis through interfering with Mek function.
Introduction
It is estimated that one in three Caucasians will develop basal cell carcinoma (BCC) in their lifetime, and the annual medical cost is estimated to be over 1 billion dollars in the US alone (Miller and Weinstock, 1994) . BCC is also a major symptom of Gorlin syndrome (Gorlin, 1987) , a rare autosomal dominant disorder with a high risk of multiple BCCs. Considerable insight into the molecular basis of basal cell carcinogenesis has come from the discovery of frequent activation of the Sonic hedgehog (Shh) pathway in BCCs. This can be attributed to loss-of-function mutations of PTCH1, which encodes Shh receptor and antagonist, through PTCH1 mutations and loss of the remaining allele (Gailani et al., 1996; Wolter et al., 1997; Xie et al., 1997a, b; Aszterbaum et al., 1998; Bodak et al., 1999) . Most PTCH1 mutations in human BCCs cause loss of PTCH1 protein function (Vorechovsky et al., 1997a, b; and reviewed in Toftgard, 2000; Epstein, 2001) . Mice that are heterozygous for a PTCH1 null mutation exhibit a high risk of cancers such as medulloblastomas, rhabdomyosarcomas, and BCCs (Goodrich et al., 1997; Aszterbaum et al., 1998; Hahn et al., 1998) , confirming that PTCH1 functions as a tumor suppressor. In addition to PTCH1, somatic mutations of smoothened (SMO), a putative seventransmembrane-domain protein of the hedgehog pathway, occur in sporadic BCCs (Reifenberger et al., 1998; Xie et al., 1998; Lam et al., 1999) . Mutant SMO can transform cultured cells and can induce BCC-like tumors when expressed in the epidermis . This finding provides additional evidence of the role of the sonic hedgehog pathway in BCCs.
Although surgery is a common procedure for BCC treatment, undesirable side effects, including scarring, and in some cases permanent damage, often occur in problematic areas of the body, especially around the eyes, mouth, and cartilage of the nose and ears. Amounting evidence supports that exogenous interferon (IFN)a or stimulating IFNa secretion is an effective way for BCC therapy, either intralesionally or topically (Grob et al., 1988; Chimenti et al., 1995; Hottiger et al., 1999) . Intratumoral injection of recombinant interferons has been shown to result in complete remission in 47-86% of patients with BCC (Grob et al., 1988 ). An immune response modifier imiquimod (3M Pharmaceuticals Inc.), which mainly stimulates secretion of cytokines such as IFNa, is an effective BCC treatment (reviewed in Vander Straten et al., 2000) . However, the underlying tumor regressing mechanisms by IFNa are still not understood.
Owing to the effectiveness of IFNa-based therapy in BCCs, which harbor alterations of the sonic hedgehog pathway, we wonder if IFNa affects hedgehog pathwaymediated cell signaling. Here we report that IFNamediated cell killing in hedgehog pathway-activated BCC cells is dependent on elevated Fas expression through interfering with mitogen-activated Erk-regulating kinase (Mek) function.
Experimental procedures

Material and reagents
CH310T1/2 cells, purchased from the American Type Culture Collection, were cultured in Basal Medium Eagle (Invitrogen) supplemented with 10% (v/v) heatinactivated fetal bovine serum with 1% L-glutamine at 371C in 5% CO 2 . A mouse BCC cell line ASZ001 (kindly provided by Dr Ervin Epstein and Dr Michelle Aszterbaum) was maintained in 154CF medium as reported previously (Xie et al., 2001) . Mouse recombinant IFNa (specific activity 4.3 Â 10 6 m/mg protein) and neutralizing antibodies of Fas-L were purchased from R&D systems. Antibodies against caspase-3, phosphop44/42, phospho-Mek and total p44/42 were purchased from Cell Signaling Inc., and antibodies against Fas from Upstate Biotechnology and Santa Cruz Biotechnology Inc. Antibodies against Fas-L were from BD transduction lab. Antibodies to mouse caspase-8 and caspase-9 were purchased from Santa Cruz Biotechnology. ]-2,5-diphenyltetrazolium bromide) was purchased from Sigma, and Dual-luciferase reporter assay systems were from Promega. Caspase-8 inhibitor Z-IETD-FMK was purchased from Calbiochem.
Colorimetric MTT assay
ASZ001 cells were plated onto 96-well plates at a density of 3000 cells/well in 100 ml of culture medium (without supplements) and cultured in an atmosphere of 5% CO 2 at 371C overnight. The next day, when cell confluency reached 60%, IFNa was added into medium to obtain final concentration of 500, 1000, 2000, 4000 and 6000 U/ml, respectively. After treatment with IFNa for 36 h, the MTT assay was performed as previously reported. Briefly, 20 ml of freshly prepared MTT (5 mg/ml in PBS) was added into each well and cells were incubated for additional 3 h at 371C. After removal of MTT, 100 ml of DMSO was added to the ASZ001 cells and the optical density (OD) was measured at 570 nm. The proliferation inhibition was calculated by dividing the mean value obtained for the respective PBS control without IFNa. The background absorbency, obtained from the wells with DMSO only, was subtracted from the test-and control-well values to yield corrected absorbency. All experiments were repeated three times.
Transient reporter analysis
The serum response element (SRE) Cis-reporting plasmid was purchased from Stratagene. Reporter-gene activity was determined in CH310T1/2 cells as described (Xie et al., 2001) . In brief, subconfluent CH310T1/2 cells in six-well plates were transiently transfected with pSRE, pRL-TK and various expressing constructs. After overnight incubation, cells were washed with PBS three times, and then the culture medium was changed with low serum medium (0.05% FBS) with or without IFNa (4000 U/ml). After 36 h, cells were collected for luciferase activity analysis using a DualLuciferase Reporter Assay System (Promega). Differences in transfection efficiency were corrected by normalizing the activity of the firefly Luciferase reporter to the activity of Renilla Luciferase internal control. Each experiment was done in duplicate and was repeated three times.
Western blot analysis
Western blot analysis was described previously (Xie et al., 2001) . Briefly, cells were lysed in protein loading buffer and proteins were separated by 10% SDS-PAGE. After electrophoresis, protein was transferred onto nitrocellulose membranes and blotted against specific antiphospho-p44/42 MAP kinase (Thr202/ Tyr204) antibody, antiphospho-Mek antibody, antiFas antibodies or others. Protein bands were revealed by an enhanced-chemiluminescence (ECL) reaction (Amersham Pharmacia Biotech).
TUNEL analysis and cell proliferation assay TUNEL assay was performed using a kit (Roche Biochemicals Inc.) according to the manufacturer's protocol. In brief, cells were fixed with 4% paraformaldehyde, and permeatilized with 0.1% Triton X-100, 0.1% sodium citrate (freshly prepared). After washing with PBS, each sample was incubated with 50 ml of TUNEL reaction mixture at 371C for 30 min. TUNEL label solution (without enzyme) was used as a negative control. A final concentration of 10 mg/ml Fas-L antibodies (purchased from R&D systems) was used to neutralize the function of Fas-L. Over 2000 cells were counted from around 40 fields under a fluorescence microscope. BrdU labeling was performed using an in situ cell proliferation kit (Roche Molecular Biochemicals) (Xie et al., 2001) . The counting was repeated three times, and the percentage from each counting was calculated.
Immunofluorescent staining of Fas expression
ASZ001 cells were cultured in chamber slides. At 60-70% of cell confluency, dominant active Mek and GFPexpressing plasmids were transfected into the cells. At 12 h post-transfection, cells were treated with IFNa (4000 m/ml) for 36 h. Immunofluorescent staining procedures were similar to TUNEL assay except that Fas antibodies (rabbit polyclonal antibodies M20 from Santa Cruz Biotechnology) were incubated with cells for 1 h at room temperature, followed by incubation with texas-red-conjugated secondary antibodies for 30 min. Fas positive cells were viewed under fluorescent microscope.
Results
IFNa-mediated apoptosis in BCCs
To understand the relevant biological consequences of IFNa, we tested the effect of IFNa on BCC cells. As no human BCC cell lines are available, we used a mouse BCC cell line, ASZ001, generated from a Gli1-expressing mouse BCC tumor induced by UV radiation in a PTC þ /À mouse (Aszterbaum et al., 1998) . Both copies of the PTC gene are lost in the ASZ001 cells, thus resembling the PTCH1 status in human BCCs. Furthermore, the ASZ001 cell line, unlike other keratinocytes tested, can grow in the absence of keratinocyte growth supplements (which contain many growth factors) and therefore is amenable to manipulation of the Ras-Erk pathway (extracellular signal-regulated kinase, Erk). Cells were either treated with IFNa (4000 U/ml) or without treatment. At 36 h after IFNa treatment, we observed significant reduction of the number of live cells, indicating that IFNa inhibits growth of ASZ001 cells ( Figure 1a ). In contrast, we did not observe any changes in cell morphology, which often represents the status of cell differentiation. This observation was further confirmed by a colorimetric MTT assay. Incubation of the cells with IFNa for 36 h decreased the cell viability in a dose-dependent manner (Figure 1b) . At a concentration of 6000 U/ml, IFNa inhibited cell growth over 60%. Thus, our data indicate that IFNa does reduce cell viability in ASZ001 cells. These data are consistent with IFN-based therapy of human BCCs that administration of IFNs results in tumor shrinkage (Grob et al., 1988; Chimenti et al., 1995; Hottiger et al., 1999) . There are at least two possibilities through which cell viability is reduced: inhibition of cell proliferation (DNA synthesis) or promotion of apoptosis. We found that addition of IFNa did not change the rate of DNA synthesis in ASZ001 cells (data not shown). In contrast, we found that IFNa increased the 
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C Li et al rate of TUNEL positive cells by threefold ( Figure 2a ). Thus, our data support that IFNa-mediated antitumor effect is through increasing the rate of apoptosis, not through inhibition of cell proliferation. This result was further confirmed by analyses of caspase cleavage, an indicator for programmed cell death, and trypan blue staining (Figure 2b and c).
IFNa prevents hedgehog signaling-mediated Erk activation
To understand the molecular basis by which IFNa mediates apoptosis in BCCs, we examined the effect of IFNa on the hedgehog signaling pathway, the pathway frequently altered in BCCs. Our previous data from sonic hedgehog-responsive C3H10T1/2 cells demonstrate that hedgehog signaling activates the Ras-Erk pathway via platelet-derived growth factor receptor alpha (PDGFRa) (Xie et al., 2001) . As a first step, we tested whether IFNa inhibits the hedgehog pathwaymediated activation of the Ras-Erk pathway in C3H10T1/2 cells. SMO agonist Ag-1.4, like sonic hedgehog, can activate the sonic hedgehog pathway in a variety of cell lines including C3H10T1/2 cells (FrankKamenetsky et al., 2002, and our unpublished observations). We found that Ag-1.4 elevated the level of phosphorylated Erk (Figure 3a) . However, in the presence of IFNa, SMO agonist-mediated activation of Erk was completely abrogated (Figure 3a) . Similarly, we found that IFNa decreased the level of phosphorylated Erk in hedgehog pathway-activated ASZ001 cells (Figure 3b ). Thus, it appears that IFNa can directly inhibit hedgehog pathway-mediated Erk phosphorylation. To understand how IFNa mediates inhibition of Erk phosphorylation, we transiently transfected expressing plasmids encoding components of the sonic hedgehog pathway and the Ras-Erk pathway to test the effect of IFNa. First, we tested the effect of IFNa on activated Erk (detected by phospho-specific antibodies) (McCormick, 1994) . Erk-2, as well as other expressing constructs (Gli1, PDGFRa and activated Raf, respectively) were cotransfected into C3H10T1/2 cells, and the level of phospho-Erk2 and total Erk were assessed by specific antibodies. Compared with the vector, Gli1, PDGFRa and activated Raf did increase phosphorylation of Erk2, as we demonstrated previously (Xie et al., 2001) . In the presence of IFNa, we observed reduced levels of Erk2 phosphorylation (Figure 3c ). This experiment suggests that IFNa inhibits hedgehog pathway-mediated activation of the Ras-Erk pathway. To confirm our data from Erk phosphorylation, we used a luciferase reporter construct of SREs as readout of the Ras-Erk pathway. We found that SMO, Gli1, PDGFRa and activated Raf stimulates the reporter activity over 6-, 14-, 16-and 34-fold, respectively (see Figure 3d ), which is consistent with our previously published results (Xie et al., 2001) . In the presence of IFNa, we found that the SRE reporter activity was dramatically decreased in each experiment (Figure 3d ) just as it inhibited Gli1-, PDGFRa-and Raf-mediated Erk phosphorylation. Under the same condition, IFNa has very little effect on a luciferase reporter for the wnt pathway (data not shown here). Thus, all these data indicate that IFNa can inhibit hedgehog pathwaymediated activation of the Ras-Erk pathway through a molecule downstream of Raf.
As IFNa is able to inhibit activated Raf, the IFNa target has to be a molecule downstream of Raf, possibly Mek. Using SRE reporter gene analysis, we found that activated Mek increased the reporter activity over 80-fold (Figure 3d ). In contrast, IFNa did not affect activated Mek in this reporter gene assay, confirming our prediction that Mek is the target for IFNa function. This reporter gene assay was further confirmed by Erk phosphorylation. IFNa was unable to block activated Mek-mediated Erk phosphorylation (Figure 3c ). Under the same condition, wild-type Mek-mediated Erk phosphorylation was inhibited by IFNa (data not shown here). These data predict that inhibition of Mek by a small molecule compound would have similar results as IFNa does. Indeed, we found that U0126, a specific Mek inhibitor, induced cleavage of caspase-3 (Figure 4a ). Thus, our data indicate that IFNa inhibits hedgehogmediated activation of the Ras-Erk pathway through interfering with Mek function. As shown later (Figure 5c ), IFNa prevents Mek phosphorylation in ASZ001 cells, suggesting that IFNa affects Mek phosphorylation. It is known that IFNa exerts its effects mostly through the interferon receptor and the Jak-Stat pathway (Darnell, 1996; Larner and Reich, 1996) , further studies are necessary to identify the molecule, which mediates the effect of IFNa on suppression of Mek phosphorylation.
IFNa induces Fas expression in BCC cells
Our data in ASZ001 cells indicate that IFNa can induce apoptosis and can interfere with Mek function. It is known that expression of Fas (CD95) can be regulated by several pathways including p53 and the Ras-Erk pathway (Fenton et al., 1998; Peli et al., 1999; Kazama and Yonehara, 2000) . To further confirm the effect of IFNa on activation of the Ras-Erk pathway, we used the SRE luciferase reporter construct. C3H10T1/2 cells were transiently transfected with a reporting plasmid driven by the SRE and various expressing constructs as indicated. pRL-TK Renilla luciferase-reporting construct (Promega) was cotransfected at the same time to each sample to normalize transfection efficiency. Cells were cultured in 0.05% FBS medium with or without IFNa (4000 U/ml) for 36 h and luciferase activity was measured. The relative luciferase activity was shown with the control sample as 1. All experiments are expressed as mean7s. (Figure 4b ). In consistent with this observation, Fas is not detectable in most human BCCs in which the hedgehog pathway is frequently activated (GutierrezSteil et al., 1998; Lee et al., 1998; Filipowicz et al., 2002, and our unpublished data) . We further demonstrated that in the presence of IFNa, SMO agonist Ag-1.4 is unable to suppress Fas expression in 10T1/2 cells (Figure 4b ). Thus, IFNa not only abrogates Ag-1.4-mediated activation of the Ras-Erk pathway, but also interferes with Ag-1.4-induced suppression of Fas expression.
The relevance of the Ras-Erk pathway in Fas regulation was further demonstrated by the fact that Mek inhibitor U0126 was sufficient to induce Fas expression in BCC cells (Figure 4a ), which is consistent with its ability to induce caspase-3 cleavage (Figure 2b ). We have shown that IFNa exerts its effects through interfering with Mek function. Thus, we predict that, after expression of dominant active Mek, ASZ001 cells will not be induced to express Fas by IFNa. We examined Fas expression following transfection of dominant active Mek into ASZ001 cells and IFNa treatment. We found that Fas was induced by IFNa in most ASZ001 cells except for those cells transfected with dominant active Mek (Figure 4c ). These data demonstrate that IFNa induces Fas expression mainly through interfering with Mek function.
The role of Fas in IFNa-mediated apoptosis in BCCs
To demonstrate the requirement of Fas/Fas ligand interactions for IFNa-mediated cell death, we used Fas-L neutralizing antibodies, which will inhibit the Fas-L/ Fas signaling axis through depleting Fas-L molecules in (Figure 5a ). Upon depletion of the Fas-L in the medium, the percentage of TUNEL positive cells was greatly reduced (Figure 5b ). As Fas-mediated cell death requires activation of caspase-3 and caspase-8, but not caspase-9 (through protein cleavage), we examined the level of full-length caspases, and found that IFNamediated cleavage of capsase-3 (a reduced level of fulllength caspase-3 and an increased level of cleaved caspase-3) was inhibited by Fas-L neutralizing antibodies (Figure 5c ). Similarly, we observed a reduced level of full-length caspase-8 in the presence of IFNa, which again was inhibited by Fas-L neutralized antibodies (Figure 5d ). In contrast, caspase-9 was not affected by IFNa, confirming that IFNa-mediated apoptosis requires the signaling axis of Fas-L/Fas (Figure 5d ). These results prompt us to predict that caspase-8 inhibitor Z-IETD-FMK should be effective in inhibiting IFNa-mediated apoptosis. Indeed, addition of Z-IETD-FMK abrogated IFN-mediated caspase-3 cleavage in BCC cells (Figure 5c ). Furthermore, we found that neither Fas-L neutralizing antibodies nor caspase-8 inhibitor Z-IETD-FMK affected the level of Fas (Figure 5c ). Similarly, IFNa-induced suppression of Erk and Mek phosphorylation was not affected by these two reagents (Figure 5c ). Thus, these data provide direct evidence that IFNa-mediated apoptosis requires a functional Fas-L/Fas signaling axis. In summary, we found that IFNa induced apoptosis in BCC cells, which was accompanied by elevated expression of Fas and inhibition of the Ras-Erk pathway. We have shown that IFNa interferes with Mek function to suppress hedgehog pathway-mediated activation of the Ras-Erk pathway. We have also demonstrated that Fas/Fas-L interactions are required for IFNa-mediated apoptosis in BCCs. Figure 6 illustrates our model of IFNa-mediated cell death in BCCs. In BCCs, activation of the sonic hedgehog pathway leads to activation of the Ras-Erk pathway, causing cell proliferation, reduced Fas expression and a low rate of apoptosis. After administration of IFNa or IFNa stimulating agents, the hedgehog pathway-induced activation of Mek is inhibited, leading to an elevated level of Fas and apoptosis.
Discussion
IFNa signaling in BCCs
IFNa is known as an immunotherapeutical reagent, but its effects in cancer cell signaling are not well understood. Several lines of evidence indicate that Mek is the ultimate target of IFNa. First, Erk phosphorylation induced by expression of wild-type Mek, but not the active form, can be abrogated by IFNa. Second, IFNa affects wild-type Mek-mediated SRE activation, but has no effects on the active form of Mek. Furthermore, IFNa inhibits SMO agonist-mediated phosphorylation of Erk ( Figure 3a) and Mek (data not shown here) in sonic hedgehog responsive C3H10T1/2 cells. IFNa also inhibits Mek phosphorylation in hedgehog pathwayactivated BCC cells (Figure 5c ). Thus, it appears that IFNa exerts its effects through interfering with Mek phosphorylation. It is known that IFNa directly binds its receptor IFNR to activate the Jak-Stat pathway (Darnell, 1996; Larner and Reich, 1996) . It will be of great interests to identify the actual molecule (s), which mediates the effect of IFNa. Identification of such molecule(s) could reveal novel mechanisms for regulating Mek activity in human cancer, which will have significant clinical applications.
Fas expression and prognosis of BCCs
Our results from C3H10T1/2 cells indicate that IFNa inhibits SMO agonist-mediated activation of the RasErk pathway (see Figure 3a for details). As a result, Erk phosphorylation will be downregulated and Fas expression will be induced (see Figure 4 for details). Thus, we predict that the level of Fas expression can be used for prognosis of BCCs. In fact, Fas is reported to be upregulated in BCCs following IFNa treatment (Buechner et al., 1997) . Our studies provide strong evidence for the involvement of the Ras-Erk pathway in regulating Fas expression. First, specific Mek inhibitor U0126 induces Fas and apoptosis in ASZ001 cells (Figure 4a ), demonstrating that inhibiting the Ras-Erk pathway is sufficient to induce apoptosis in BCC cells. Second, expression of constitutively active Mek, but not the wild-type form, prevents IFNa from inducing Fas expression, demonstrating the role of Mek in regulating Fas expression. It is known that activation of the RasErk pathway, as a consequence of the hedgehog pathway activation, occur frequently in human BCCs. (Buechner et al., 1997; Gutierrez-Steil et al., 1998; Romerio and Zella, 2002) . To demonstrate the requirement of Fas expression for cell death, we depleted Fas-L with neutralizing antibodies, and we detected inhibition of apoptosis (see Figure 5 for details). It is known that Fasmediated apoptosis causes cleavage of caspase-8, but not caspase-9. Indeed, we found a decreased level of caspase-8 after addition of IFNa whereas the level of caspase-9 was not changed (Figure 5d ). Further experiments demonstrate that caspase-8 inhibitor can effectively block IFNa-mediated cell death (see Figure 5c ). Thus, our data provide direct evidence that active Fas/ Fas-L interactions are necessary for IFNa-mediated apoptosis in BCCs.
Regulation of Fas by the Ras-Erk pathway
Previous reports indicate that Fas expression can be regulated by several pathways including the Ras pathway. It appears that ras can directly regulate the transcription of Fas (Peli et al., 1999) . We have analysed sequences of human and mouse Fas and found multiple copies of multiple copies of SREs and Ras-responsive elements in the promoter region, suggesting that Ras/ Raf/Erk pathway can directly regulate transcription of Fas of human and mouse. Using different mutant forms of Ras, it is demonstrated that activity of the Ras-Erk pathway is involved in Fas regulation (Kazama and Yonehara, 2000) . We demonstrate that Fas can be induced in ASZ001 cells by Mek inhibitor U0126 (see Figure 4a ) and that active Mek prevents IFNa from inducing Fas expression, indicating that Fas expression is regulated in BCCs mostly through Mek function.
